Taiwan Biomaterial Co., Ltd.

As of June 30, 2026, Taiwan Biomaterial Co., Ltd. carries a market capitalization of 1.60B, placing it among publicly traded companies globally. Its enterprise value stands at 1.40B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Taiwan Biomaterial Co., Ltd. has 42.00M shares outstanding.

As of June 30, 2026, Taiwan Biomaterial Co., Ltd. trades at a trailing price-to-earnings ratio of 48.16. The price-to-sales ratio is 8.76, and the price-to-book ratio stands at 2.48.

As of June 30, 2026, Taiwan Biomaterial Co., Ltd. trades at an EV/EBITDA multiple of 40.11 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.69 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 75.93 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.40B versus a market cap of 1.60B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Taiwan Biomaterial Co., Ltd. maintains a current ratio of 10.52, meaning it holds 10.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.09, indicating elevated leverage, while an interest coverage ratio of 48.32 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Taiwan Biomaterial Co., Ltd. posted a return on equity (ROE) of 5.12, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.63 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.56, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.83, useful for judging operating efficiency across full business cycles. The company generates approximately 4.22M in revenue per employee across its workforce of 43.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.32 indicates how many times Taiwan Biomaterial Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Taiwan Biomaterial Co., Ltd.'s stock has declined approximately 42.06% over the past 52 weeks. The 50-day moving average sits at 35.95, while the 200-day moving average is 40.24.

Over the twelve months ended June 30, 2026, Taiwan Biomaterial Co., Ltd. generated 182.32M in revenue and converted that into 33.16M in net income, yielding earnings per share of 0.79. EBITDA reached 34.94M, while operating income came in at 18.46M.

As of June 30, 2026, Taiwan Biomaterial Co., Ltd. holds 246.77M in cash and equivalents against 52.07M in total debt, resulting in a net debt position of -184.27M. Total book value stands at 643.85M, with working capital of 362.68M providing operational flexibility.

Taiwan Biomaterial Co., Ltd. produced -33.92M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -8.57M in capital expenditures, free cash flow totaled -42.49M - equivalent to -1.01 per share.

Over the twelve months ended June 30, 2026, Taiwan Biomaterial Co., Ltd. posted a gross margin of 55.97, reflecting its pricing power and cost economics. The operating margin of 10.12 and net profit margin of 18.19 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Taiwan Biomaterial Co., Ltd. paid dividends of 1.00 per share. The dividend payout ratio of 126.65 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -2.65: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 2.80, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Taiwan Biomaterial Co., Ltd. shareholders.

Taiwan Biomaterial Co., Ltd.'s most recent stock split took place on December 20, 2021 with a 117:121 split ratio.

As of June 30, 2026, Taiwan Biomaterial Co., Ltd. has an Altman Z-Score of 11.96, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.